공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

유전자 치료 시장 규모, 점유율, 동향 분석 : 적응증(거대 B세포 림프종, 베타 탈라세미아 메이저/SCD), 벡터 유형(렌티바이러스, AAV), 지역별 예측(2021-2028년)

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-cell Lymphoma, Beta-Thalassemia Major/SCD), By Vector Type (Lentivirus, AAV), By Region, And Segment Forecasts, 2021 - 2028

리서치사 Grand View Research, Inc.
발행일 2021년 02월 상품 코드 989688
페이지 정보 영문 180 Pages
가격
US $ 5,950 ₩ 6,725,000 Unprintable PDF (Single User License)
US $ 6,950 ₩ 7,855,000 Printable PDF (5-User License)
US $ 8,950 ₩ 10,116,000 Printable PDF (Enterprise License)


유전자 치료 시장 규모, 점유율, 동향 분석 : 적응증(거대 B세포 림프종, 베타 탈라세미아 메이저/SCD), 벡터 유형(렌티바이러스, AAV), 지역별 예측(2021-2028년) Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-cell Lymphoma, Beta-Thalassemia Major/SCD), By Vector Type (Lentivirus, AAV), By Region, And Segment Forecasts, 2021 - 2028
발행일 : 2021년 02월 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 유전자 치료 시장 규모는 예측 기간 중 20.4%의 CAGR로 추이하며, 2028년에는 100억 달러 규모로 성장할 것으로 예측됩니다. 암의 유병률 증가, 암의 유효 치료법 결여, 첨단 암치료제의 임상시험 추진 등의 요인이 이 시장의 성장을 촉진하고 있습니다.

세계의 유전자 치료 시장을 조사했으며, 시장의 정의와 개요, 신종 코로나바이러스 감염증(COVID-19) 및 기타 시장 영향요인 분석, 법규제 환경, 파이프라인 분석, 시장 규모의 추이·예측, 적응증·벡터 유형·지역/주요 국가 등 각종 부문별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 개요

제2장 조사 방법

제3장 시장 가변 요인·동향·전망

  • 시장 동향·전망
  • 시장 세분화
  • 시장 역학
  • 규제 프레임워크
  • 주요 거래·전략적 제휴
  • 파이프라인 분석
  • 결제·가격결정 모델
  • SWOT 분석
  • Porter의 산업 분석
  • COVID-19 : 영향 분석

제4장 시장 예측·동향 분석 : 적응증별

  • 급성 림프구성 백혈병(ALL)
  • 유전성 망막 질환
  • 거대 B세포 림프종
  • 아데노신 디아미나제(ADA) - SCID(Deficient Severe Combined Immunodeficiency)
  • 흑색종
  • 베타 탈라세미아 메이저/겸상 적혈구증(SCD)
  • 두경부 편평상피암
  • 말초동맥 질환
  • 척수성 근위축증(SMA)
  • 기타

제5장 시장 예측·동향 분석 : 벡터 유형별

  • 렌티바이러스 벡터
  • 아데노 연관 바이러스(AAV) 벡터
  • 레트로바이러스 & 감마레트로바이러스 벡터
  • 개변 단순 헤르페스 바이러스
  • 아데노바이러스 벡터
  • 비바이러스 플라스미드

제6장 시장 예측·동향 분석 : 지역·주요 국가별

  • 시장 점유율 실적·예측
  • 시장 규모의 추이·예측
  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제7장 기업 개요

KSA 21.02.23

List of Tables

  • TABLE 1 Ongoing projects for CAR T-cell therapies
  • TABLE 2 Non-viral DNA vectors (non-replicating) in gene therapy trials
  • TABLE 3 Some of the examples of molecules under development based on lentiviral vectors
  • TABLE 4 Molecules in development based on AAV vectors
  • TABLE 5 North America gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 6 North America gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 7 The U.S. gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 8 The U.S. gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 9 Canada gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 10 Canada gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 11 Europe gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 12 Europe gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 13 Asia Pacific gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 14 Asia Pacific gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 15 China gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 16 China gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 17 Japan gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 18 Japan gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 19 Russia gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 20 Russia gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 21 Australia gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 22 Australia gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 23 RoW gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 24 RoW gene therapy market, by vector type, 2017 - 2028 (USD Million)

List of Figures

  • FIG. 1 Market summary (USD Million)
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Global gene therapy pipeline as of 2017, by phase of trial
  • FIG. 12 Global cancer incidence, as of 2019/2020
  • FIG. 13 Market restraint relevance analysis (Current & future impact)
  • FIG. 14 Gene therapy prices by eligible patients per year
  • FIG. 15 Annual Investment in the CAR-T Space, 2013-2026
  • FIG. 16 Global financings in cell therapy, 2017-2019
  • FIG. 17 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017
  • FIG. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 19 Porter's Five Forces Analysis
  • FIG. 20 Gene therapy market: Indication type outlook key takeaways
  • FIG. 21 Gene therapy market: Indication type movement analysis
  • FIG. 22 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2017 - 2028 (USD Million)
  • FIG. 23 Global gene therapy market for inherited retinal disease, 2017 - 2028 (USD Million)
  • FIG. 24 Global gene therapy market for large B-cell lymphoma, 2017 - 2028 (USD Million)
  • FIG. 25 Global gene therapy market for ADA-SCID, 2017 - 2028 (USD Million)
  • FIG. 26 Global gene therapy market for melanoma (lesions), 2017 - 2028 (USD Million)
  • FIG. 27 Global gene therapy market for Beta-Thalassemia Major/SCD, 2017 - 2028 (USD Million)
  • FIG. 28 Global gene therapy market for head & neck squamous cell carcinoma, 2017 - 2028 (USD Million)
  • FIG. 29 Global gene therapy market for peripheral arterial disease, 2017 - 2028 (USD Million)
  • FIG. 30 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2017 - 2028 (USD Million)
  • FIG. 31 Global gene therapy market for other indications, 2017 - 2028 (USD Million)
  • FIG. 32 Gene therapy market vector type outlook: Key takeaways
  • FIG. 33 Gene therapy market: Vector type movement analysis
  • FIG. 34 Global lentivirus-based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 35 Global AAV-based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 36 Global retrovirus vectors-based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 37 Global modified herpes simplex virus vectors -based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 38 Global adenovirus vectors -based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 39 Global plasmids-based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 40 Regional market place: Key takeaway
  • FIG. 41 Gene therapy regional outlook, 2020 & 2028
  • FIG. 42 North America gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 43 The U.S. gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 44 Canada gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 45 Europe gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 46 Asia Pacific gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 47 China gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 48 Japan gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 49 Russia gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 50 Australia gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 51 RoW gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 52 Strategy framework

Gene Therapy Market Growth & Trends

The global gene therapy market size is expected to reach USD 10.0 billion by 2028 registering a CAGR of 20.4% during the forecast period, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer coupled with the lack of effective treatment for the disease. Constant expansion of cancer genetic studies has deciphered relevant information about cancer-related molecular signatures.

This has driven the clinical trials for advanced cancer therapeutics, thereby driving the market growth. In addition, expansion of this mode of treatment in non-cancer applications with approval of therapies, such as approval of Bluebird Bio's Zynteglo in June 2019 for B-thalassemia and others, demonstrates the shift in the preferences of companies towards other unsaturated segments.

Various universities and institutes are observed to exhibit a broad portfolio in the pipeline, which is anticipated to boost revenue generation in the future. The market is anticipated to witnesses a short-term revenue slowdown due to a shift in focus and delay in product launches. However, initiatives for developing novel trial designs, improving the regulatory environment, and managing the supply chain are expected to play a critical role in minimizing the impact of the current global crisis.

Gene Therapy Market Report Highlights

  • Viral vectors have proven their efficiency as a method for effective gene deliveries. As a result, a substantial number of research communities and biotechnology companies have designed their gene therapy programs based on viral vectors
  • Moreover, most of currently FDA-secured products involve the use of viral vectors, which contributes to the dominance of the viral vectors segment
  • Due to the approval and huge success of lentivirus-based Kymriah and retrovirus-based Yescarta, retrovirus and lentivirus are also among the key revenue-generating segments
  • Cancer has led the revenue flow in the market over the past few years and is expected to maintain its dominance in the forecast period
  • The presence of approved products for various cancer forms including Large B-cell lymphoma, Acute Lymphoblastic Leukemia (ALL), and melanoma has resulted in the dominance of this segment
  • The U.S. is recognized as the hub for clinical trials related to gene therapy. This has significantly impacted the revenue growth of the North America market
  • Also, the success of Yescarta and Kymriah in the U.S. as the first approved CAR-t therapy programs has driven huge investments by various government agencies, sponsors, and key companies in this region
  • Major market participants are partnering with other key stakeholders via signing licensing, commercialization, and development deals to enhance their worldwide business operations
  • For instance, in June 2020, uniQure announced a license agreement with CSL Behring for the commercialization of hemophilia B gene therapy

Table of Contents

Chapter 1 Gene Therapy Makret: Executive Summary

  • 1.1 Market Summary

Chapter 2 Gene Therapy Makret: Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information Or Data Analysis
  • 2.3 Market Model
    • 2.3.1 Historic And Base Year Estimates
    • 2.3.2 Forecast Analysis
    • 2.3.3 Study Of Approved Therapies By Disease Incidence
    • 2.3.4 Study Of Approved Therapies By Vector
    • 2.3.5 Region-Wise Approval

Chapter 3 Gene Therapy Makret: Market Variables, Trends, & Scope

  • 3.1 Market Trends & Outlook
  • 3.2 Market Segmentation
  • 3.3 Market Dynamics
    • 3.3.1 Market driver analysis
      • 3.3.1.1 Robust gene therapy pipeline
      • 3.3.1.2 Introduction of technological advancements
      • 3.3.1.3 Increasing investment from the companies and partnerships
      • 3.3.1.4 Growing prevalence of target diseases and increased demand for innovative medicine
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 Absence of effective Diagnosis Framework
      • 3.3.2.2 High prices of gene therapy
    • 3.3.3 Market opportunity analysis
      • 3.3.3.1 Rising investment for adoptive T cell transfer approaches of disease treatment
      • 3.3.3.2 Facility expansion for cell and gene therapies
      • 3.3.3.3 Technological advancements in manufacturing vectors
    • 3.3.4 Market challenge analysis
      • 3.3.4.1 Production capacity challenges
      • 3.3.4.2 Manufacturing challenges pertaining to large-scale production of vectors
  • 3.4 Regulatory Framework
  • 3.5 Major Deals & Strategic Alliances Analysis
    • 3.5.1 Mergers & acquisitions
    • 3.5.2 Collaborations & partnerships
  • 3.6 Pipeline Analysis
  • 3.7 Payment & Pricing Models
    • 3.7.1 Payment models for innovative therapies
  • 3.8 SWOT analysis, by factor (Political & legal, economic, and technological)
  • 3.9 Porter's Five Forces Analysis
  • 3.10 COVID-19 Impact Analysis
    • 3.10.1 Key Market Initiatives
    • 3.10.2 Conclusion

Chapter 4 Gene Therapy Makret: Indication Business Analysis

  • 4.1 Gene therapy market: Indication Movement Analysis
  • 4.2 Acute Lymphoblastic Leukemia (ALL)
    • 4.2.1 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2017 - 2028 (USD Million)
  • 4.3 Inherited Retinal Disease
    • 4.3.1 Global gene therapy market for inherited retinal disease, 2017 - 2028 (USD Million)
  • 4.4 Large B-cell Lymphoma
    • 4.4.1 Global gene therapy market for large B-cell lymphoma, 2017 - 2028 (USD Million)
  • 4.5 Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)
    • 4.5.1 Global gene therapy market for ADA-SCID, 2017 - 2028 (USD Million)
  • 4.6 Melanoma (Lesions)
    • 4.6.1 Global gene therapy market for melanoma (lesions), 2017 - 2028 (USD Million)
  • 4.7 Beta-Thalassemia Major/Sickle Cell Disease (SCD)
    • 4.7.1 Global gene therapy market for Beta-Thalassemia Major/SCD, 2017 - 2028 (USD Million)
  • 4.8 Head & Neck Squamous Cell Carcinoma
    • 4.8.1 Global gene therapy market for head & neck squamous cell carcinoma, 2017 - 2028 (USD Million)
  • 4.9 Peripheral Arterial Disease
    • 4.9.1 Global gene therapy market for peripheral arterial disease, 2017 - 2028 (USD Million)
  • 4.10 Spinal Muscular Atrophy (SMA)
    • 4.10.1 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2017 - 2028 (USD Million)
  • 4.11 Others
    • 4.11.1 Global gene therapy market for Others, 2017 - 2028 (USD Million)

Chapter 5 Gene Therapy Makret: Vector Type Business Analysis

  • 5.1 Gene Therapy Market: Vector Type Movement Analysis
  • 5.2 Gene Therapy Market: Technology Movement Analysis
  • 5.3 Lentiviral Vectors
    • 5.3.1 Global lentivirus-based gene therapy market, 2017 - 2028 (USD Million)
  • 5.4 Adeno-Associated Viral (AAV) Vectors
    • 5.4.1 Global AAV-based gene therapy market, 2017 - 2028 (USD Million)
  • 5.5 RetroVirus & gamma RetroVirus Vectors
    • 5.5.1 Global RetroVirus & gamma RetroVirus vectors-based gene therapy market, 2017 - 2028 (USD Million)
  • 5.6 Modified Herpes Simplex Virus
    • 5.6.1 Global modified herpes simplex virus vectors-based gene therapy market, 2017 - 2028 (USD Million)
  • 5.7 Adenovirus Vectors
    • 5.7.1 Global adenovirus vectors -based gene therapy market, 2017 - 2028 (USD Million)
  • 5.8 Non-viral Plasmid
    • 5.8.1 Global Non-viral plasmid-based gene therapy market, 2017 - 2028 (USD Million)

Chapter 6 Gene Therapy Makret: Regional Business Analysis

  • 6.1 Gene Therapy Market Share, By Region
  • 6.2 Gene Therapy Market: Regional Movement Analysis
  • 6.3 North America
    • 6.3.1 North America Gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.2 The U.S.
      • 6.3.2.1 The U.S. gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.3.2.2 The U.S. gene therapy market, by vector type, 2017 - 2028 (USD Million)
    • 6.3.3 Canada
      • 6.3.3.1 Canada gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.3.3.2 Canada gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • 6.4 Europe
    • 6.4.1 Europe gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
  • 6.5 Asia Pacific
    • 6.5.1 Asia Pacific gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.5.2 Japan
      • 6.5.2.1 Japan gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.5.2.2 Japan gene therapy market, by vector type, 2017 - 2028 (USD Million)
    • 6.5.3 China
      • 6.5.2.1 China gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.5.2.2 China gene therapy market, by vector type, 2017 - 2028 (USD Million)
    • 6.5.4 Russia
      • 6.5.4.1 Russia gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.5.4.2 Russia gene therapy market, by vector type, 2017 - 2028 (USD Million)
    • 6.5.5 Australia
      • 6.5.5.1 Australia gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.5.5.2 Australia gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • 6.6 RoW
    • 6.6.1 RoW gene therapy market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 7 GENE THERAPY MAKRET: COMPANY Profiles

  • 7.1 Company Profiles
    • 7.1.1 REGENXBIO, Inc.
      • 7.1.1.1 Company overview
      • 7.1.1.2 Financial performance
      • 7.1.1.3 Product benchmarking
      • 7.1.1.4 Strategic Initiatives
    • 7.1.2 Oxford BioMedica plc
      • 7.1.2.1 Company overview
      • 7.1.2.2 Financial performance
      • 7.1.2.3 Product benchmarking
      • 7.1.2.4 Strategic Initiatives
    • 7.1.3 Voyager Therapeutics
      • 7.1.3.1 Company overview
      • 7.1.3.2 Financial performance
      • 7.1.3.3 Product benchmarking
      • 7.1.3.4 Strategic Initiatives
    • 7.1.4 Human Stem Cells Institute
      • 7.1.4.1 Company overview
      • 7.1.4.2 Financial performance
      • 7.1.4.3 Product benchmarking
      • 7.1.4.4 Strategic Initiatives
    • 7.1.5 Dimension Therapeutics, Inc.
      • 7.1.5.1 Company overview
      • 7.1.5.1.1 Financial performance
      • 7.1.5.2 Product benchmarking
      • 7.1.5.3 Strategic Initiatives
    • 7.1.6 Bristol-Myers Squibb Company
      • 7.1.6.1 Company overview
      • 7.1.6.1.1 Celgene Corporation
      • 7.1.6.2 Financial performance (Bristol-Myers Squibb)
      • 7.1.6.2.1 Financial performance (Celgene Corporation)
      • 7.1.6.3 Product benchmarking (Bristol-Myers Squibb)
      • 7.1.6.3.1 Product benchmarking (Celgene)
      • 7.1.6.4 Strategic Initiatives
    • 7.1.7 Sanofi
      • 7.1.7.1 Company overview
      • 7.1.7.2 Financial performance
      • 7.1.7.3 Product benchmarking
      • 7.1.7.4 Strategic Initiatives
    • 7.1.8 Applied Genetic Technologies Corporation
      • 7.1.8.1 Company overview
      • 7.1.8.2 Financial performance
      • 7.1.8.3 Product benchmarking
      • 7.1.8.4 Strategic Initiatives
    • 7.1.9 F. Hoffmann-La Roche Ltd.
      • 7.1.9.1 Company overview
      • 7.1.9.1.1 Spark Therapeutics, Inc.
      • 7.1.9.2 Financial performance
      • 7.1.9.2.1 Financial performance
      • 7.1.9.3 Product benchmarking
      • 7.1.9.4 Strategic Initiatives
    • 7.1.10 bluebird Bio, Inc.
      • 7.1.10.1 Company overview
      • 7.1.10.2 Financial performance
      • 7.1.10.3 Product benchmarking
      • 7.1.10.4 Strategic Initiatives
    • 7.1.11 Novartis AG
      • 7.1.11.1 Company overview
      • 7.1.11.1.1 AveXis, Inc.
      • 7.1.11.2 Financial performance
      • 7.1.11.2.1 Financial performance (AveXis)
      • 7.1.11.3 Product benchmarking
      • 7.1.11.4 Strategic Initiatives
      • 7.1.11.4.1 Strategic Initiatives
    • 7.1.12 Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
      • 7.1.12.1 Company overview
      • 7.1.12.2 Financial performance
      • 7.1.12.3 Product benchmarking
      • 7.1.12.4 Strategic Initiatives
    • 7.1.13 UniQure N.V.
      • 7.1.13.1 Company overview
      • 7.1.13.2 Financial performance
      • 7.1.13.3 Product benchmarking
      • 7.1.13.4 Strategic Initiatives
    • 7.1.14 Shire Plc
      • 7.1.14.1 Company overview
      • 7.1.14.2 Financial performance
      • 7.1.14.3 Product benchmarking
      • 7.1.14.4 Strategic Initiatives
    • 7.1.15 Cellectis S.A.
      • 7.1.15.1 Company overview
      • 7.1.15.2 Financial performance
      • 7.1.15.3 Product benchmarking
      • 7.1.15.4 Strategic Initiatives
    • 7.1.16 Sangamo Therapeutics, Inc.
      • 7.1.16.1 Company overview
      • 7.1.16.2 Financial performance
      • 7.1.16.3 Product benchmarking
      • 7.1.16.4 Strategic Initiatives
    • 7.1.17 Orchard Therapeutics
      • 7.1.17.1 Company overview
      • 7.1.17.2 Financial performance
      • 7.1.17.3 Product benchmarking
      • 7.1.17.4 Strategic Initiatives
    • 7.1.18 Gilead Lifesciences, Inc.
      • 7.1.18.1 Company overview
      • 7.1.18.2 Financial Performance
      • 7.1.18.3 Product benchmarking
      • 7.1.18.4 Strategic Initiatives
    • 7.1.19 BENITEC BIOPHARMA
      • 7.1.19.1 Company overview
      • 7.1.19.2 Financial Performance
      • 7.1.19.3 Product benchmarking
      • 7.1.19.4 Strategic Initiatives
    • 7.1.20 Sibiono GeneTech Co., Ltd
      • 7.1.20.1 Company overview
      • 7.1.20.2 Product benchmarking
    • 7.1.21 Shanghai Sunway Biotech Co., Ltd.
      • 7.1.21.1 Company overview
      • 7.1.21.2 Product benchmarking
    • 7.1.22 Gensight Biologics S.A.
      • 7.1.22.1 Company overview
      • 7.1.22.2 Financial performance
      • 7.1.22.3 Product benchmarking
      • 7.1.22.4 Strategic initiatives
    • 7.1.23 Transgene
      • 7.1.23.1 Company overview
      • 7.1.23.2 Financial performance
      • 7.1.23.3 Product benchmarking
      • 7.1.23.4 Strategic initiatives
    • 7.1.24 Calimmune, Inc.
      • 7.1.24.1 Company overview
      • 7.1.24.2 Product benchmarking
      • 7.1.24.3 Strategic initiatives
    • 7.1.25 Epeius Biotechnologies Corp.
      • 7.1.25.1 Company overview
      • 7.1.25.2 Financial performance
      • 7.1.25.3 Product benchmarking
    • 7.1.26 Astellas Pharma Inc.
      • 7.1.26.1 Company overview
      • 7.1.26.2 Audentes Therapeutics, Inc.
      • 7.1.26.2.1 Company overview
      • 7.1.26.3 Financial performance
      • 7.1.26.3.1 Financial performance
      • 7.1.26.4 Product benchmarking
      • 7.1.26.5 Strategic initiatives
    • 7.1.27 American Gene Technologies
      • 7.1.27.1 Company overview
      • 7.1.27.2 Product benchmarking
      • 7.1.27.3 Strategic initiatives
    • 7.1.28 BioMarin Pharmaceuticals, Inc.
      • 7.1.28.1 Company overview
      • 7.1.28.2 Financial performance
      • 7.1.28.3 Product benchmarking
      • 7.1.28.4 Strategic initiatives
Back to Top
전화 문의
F A Q